Secondary Malignancy Risk Following Proton vs. X-ray Radiotherapy of Thymic Epithelial Tumors: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk.
intensity-modulated radiotherapy (IMRT)
photon radiotherapy
proton therapy
radiation-induced cancers
thymic carcinoma
thymoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 May 2022
13 May 2022
Historique:
received:
01
11
2021
revised:
22
04
2022
accepted:
11
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Proton beam radiotherapy (PBT) offers physical dose advantages that might reduce the risk for secondary malignancies (SM). The aim of the current study is to calculate the risk for SM after X-ray-based 3D conformal (3DCRT) radiotherapy, intensity-modulated radiotherapy (IMRT), and active pencil beam scanned proton therapy (PBS) in patients treated for thymic malignancies. Comparative treatment plans for each of the different treatment modalities were generated for 17 patients. The risk for radiation-induced SM was estimated using two distinct prediction models-the Dasu and the Schneider model. The total and fatal SM risks estimated using the Dasu model demonstrated significant reductions with the use of PBS relative to both 3DCRT and IMRT for all independent thoracic organs analyzed with the exception of the thyroid gland ( PBS achieved superior sparing of relevant OARs compared to 3DCRT and IMRT, leading to a lower risk for radiation-induced SM. PBS should therefore be considered in patients diagnosed with thymic malignancies, particularly young female patients.
Sections du résumé
BACKGROUND
BACKGROUND
Proton beam radiotherapy (PBT) offers physical dose advantages that might reduce the risk for secondary malignancies (SM). The aim of the current study is to calculate the risk for SM after X-ray-based 3D conformal (3DCRT) radiotherapy, intensity-modulated radiotherapy (IMRT), and active pencil beam scanned proton therapy (PBS) in patients treated for thymic malignancies.
METHODS
METHODS
Comparative treatment plans for each of the different treatment modalities were generated for 17 patients. The risk for radiation-induced SM was estimated using two distinct prediction models-the Dasu and the Schneider model.
RESULTS
RESULTS
The total and fatal SM risks estimated using the Dasu model demonstrated significant reductions with the use of PBS relative to both 3DCRT and IMRT for all independent thoracic organs analyzed with the exception of the thyroid gland (
CONCLUSIONS
CONCLUSIONS
PBS achieved superior sparing of relevant OARs compared to 3DCRT and IMRT, leading to a lower risk for radiation-induced SM. PBS should therefore be considered in patients diagnosed with thymic malignancies, particularly young female patients.
Identifiants
pubmed: 35626013
pii: cancers14102409
doi: 10.3390/cancers14102409
pmc: PMC9139629
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Z Med Phys. 2005;15(1):31-7
pubmed: 15830782
Asian Cardiovasc Thorac Ann. 2018 May;26(4):290-295
pubmed: 29528688
Bull Cancer. 2013 Dec;100(12):1333-42
pubmed: 24257106
Transl Lung Cancer Res. 2018 Apr;7(2):106-113
pubmed: 29876309
Future Oncol. 2018 Aug;14(19):1943-1951
pubmed: 30081670
Cancer. 2001 Nov 1;92(9):2406-11
pubmed: 11745297
Int J Cancer. 2003 Dec 10;107(5):868-70
pubmed: 14566841
Ann Oncol. 2015 Sep;26 Suppl 5:v40-55
pubmed: 26314779
Acta Oncol. 1999;38(2):137-45
pubmed: 10227433
Int J Cancer. 2003 Jul 1;105(4):546-51
pubmed: 12712448
Acta Oncol. 2021 May;60(5):649-652
pubmed: 33629926
Acta Oncol. 2005;44(4):339-47
pubmed: 16120542
Radiother Oncol. 2016 Mar;118(3):504-9
pubmed: 26895711
Int J Cancer. 2011 Jun 1;128(11):2688-94
pubmed: 20669226
J Thorac Dis. 2018 Aug;10(Suppl 21):S2555-S2564
pubmed: 30206499
J Thorac Oncol. 2015 Oct;10(10):1383-95
pubmed: 26295375
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1510-5
pubmed: 15817357
J Thorac Oncol. 2017 Apr;12(4):734-744
pubmed: 28126540
Phys Med. 2017 Oct;42:263-270
pubmed: 28366554
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1743-8
pubmed: 21847057
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
Acta Oncol. 2018 Dec;57(12):1713-1720
pubmed: 30264630
Clin Lung Cancer. 2016 Sep;17(5):362-366
pubmed: 27372386
Strahlenther Onkol. 2016 Nov;192(11):770-779
pubmed: 27334276
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):427-433
pubmed: 28871993